Proposal 4:
Approval of
the Private Placement
We are seeking stockholder
approval, for purposes of complying with Listing Rule 5635(d)
of The Nasdaq Stock Market LLC (“Listing Rule 5635(d)”), for
the sale in a private placement of units comprised of
(i) 1,500,000 shares of the Company’s common stock, par value
$0.01 (the “Private Placement Shares”), and (ii) warrants
exercisable into 1,500,000 shares of the Company’s common stock at
an exercise price of $11.00 per share (the “Warrants”), with
such units being sold for $10.00 per unit (the “Private
Placement”).
The information set forth in
this Proposal No. 4 is qualified in its entirety by reference to
the full text of the form of SPA, form of RRA, the form of VSA
(each as defined below) and the Form of Common Stock Purchase
Warrant attached as exhibits 10.1, 10.2, 10.3 and 4.1,
respectively, to our Current Report on Form 8-K filed with the SEC
on June 30, 2022. Stockholders are urged to carefully read these
documents.
Background
On June 26, 2022, we
entered into (i) a securities purchase agreement (the “SPA”)
with Armistice Capital Master Fund Ltd. (“Armistice”) pursuant to
which Armistice agreed to purchase the Private Placement Shares and
the Warrants for an aggregate purchase price of $15 million
and (ii) a registration rights agreement with Armistice (the
“RRA”), pursuant to which the Company will file a registration
statement covering the Private Placement Shares and the shares of
common stock underlying the Warrants within 15 days of the
date of execution of the RRA (the “Registration Statement”). The
Private Placement closed on June 29, 2022.
The Warrants will become
exercisable upon the earlier of (i) effective date of the
Registration Statement and (ii) 90 days from the closing
of the Private Placement, into shares of the Company’s common stock
at an exercise price of $11.00 per share for a term of
five years from the date the Warrants become exercisable.
Exercise of the Warrants is subject to a condition that the Company
shall not effect any exercise if after giving effect to such
exercise Armistice would beneficially own in excess of 4.99% of the
total outstanding shares of the Company’s common
stock.
The SPA contains a provision
providing that, until the Company obtains stockholder approval for
the Private Placement, the Warrants cannot be exercised into shares
that, taken together with the shares previously issued pursuant to
the Private Placement, aggregate to more than 19.9% of the
Company’s total outstanding shares of common stock or of the total
voting power of the Company’s securities as of June 26, 2022,
the date of execution of the SPA.
On June 26, 2022, Amin J.
Khoury PhD (Hon), Lewis C. Pell, David Helfet M.D. and Dateline TV
Holdings, Inc. (the “Majority Stockholders”), representing
approximately 65% of the voting power of the Company’s outstanding
shares of common stock as of May 23, 2022, entered into a
voting support agreement (the “VSA”) pursuant to which the Majority
Stockholders committed to attending the Annual Meeting or otherwise
causing their respective shares of the Company’s common stock (the
“Covered Shares”) to be counted as present at the Annual Meeting
for the purpose of establishing a quorum and further committed to
voting or causing their respective Covered Shares to be voted in
favor of this Proposal No. 4.
The Company gained U.S. Food
and Drug Administration clearance to market and sell its Pūrgo
device as a Class II Medical Device on June 1, 2022. The
Company’s strategy includes continuously evaluating a wide range of
strategic opportunities including acquisitions. As part of that
strategy, the Company is in discussions with several acquisition
candidates and may use the proceeds of the Private Placement
together with other sources of capital to effect transactions that
the Company believes would substantially increase revenues,
distribution and selling capability, and expand product lines, and,
most importantly, add sensor and monitoring technology to enable
the Company to effect its recurring revenue “Safe Air As a Service”
model. The Company’s goal is to provide actionable data to clients
through the internet of things to enable clients to provide Indoor
Air Quality as part of their Indoor Environmental Quality
initiatives. The Company currently has no material agreements or
arrangements with any of the several acquisition candidates and
there can be no assurance that any of these acquisitions, or any
others, will be consummated.